Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation

Haematologica

Volumn 93, Issue 9, 2008, Pages 1343-1350

  Ayuk, Francis ^a   Perez Simon, José A ^b   Shimoni, Avichai ^c   Sureda, Anna ^d   Zabelina, Tatjana ^a   Schwerdtfeger, Rainer ^e   Martino, Rodrigo ^d   Sayer, Herbert Gottfried ^f   Alegre, Adrián ^g   Lahuerta, Juan José ^h   Atanackovic, Djordje ^a   Wolschke, Christine ^a   Nagler, Arnon ^c   Zander, Axel R ^a   San Miguel, Jesús F ^b   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c SHEBA MEDICAL CENTER   (Israel)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e DKD   (Germany)

^f FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Allogeneic stem cell transplantation; Antilymphocyte globulin; Antithymocyte globulin; Multiple myeloma; Reduced intensity conditioning

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; ITRACONAZOLE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA CELL LINE; LEUKOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PNEUMOCYSTIS PNEUMONIA; SURVIVAL RATE; T CELL DEPLETION; TREATMENT RESPONSE;

ADULT; AGED; ANTILYMPHOCYTE SERUM; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; JURKAT CELLS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; RECURRENCE; SIBLINGS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 50849088327     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12665     Document Type: Article

References (36)

1. Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, et al. New drugs for treatment of multiple myeloma. Lancet Oncol 2004;5:430-42.
2. Attal M, Harousseau JL,Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
3. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
4. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a prospective controlled trial. Blood 2004;104:3052-7.
5. Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:4711-8.
6. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose reduced allograft (IMF99-03) with tandem autologous stem cell transplantation (IMF99-04) in high-risk de novo multiple myeloma. Blood 2006;107:3474-80.
7. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110-20.
8. Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, et al. CD20-directed serotherapy in patients with multiple myeloma: biological considerations and the therapeutic applications. J Immunother 2002;25:72-81.
9. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 2004;64:2846-52.
10. Kumar S, Kimlinger TK, Lust JA, Donavan K, Witzig TE. Expression of CD52 on plasma cells in plasma cell proliferation disorders. Blood 2003;102:1075-7.
11. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, et al. CD74 is expressed by multiple myeloma and is a promising target for therapies. Clin Cancer Res 2004;10:6606-11.
12. Mihara M, Shiina M, Nishimoto N, Yoshizaki K, Kishimoto T, Akamatsu K. Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis. J Rheumatol 2004;31:1132-8.
13. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755-60.
14. Nagler A, Aker M, Or R, Naparstek E, Varadi G, Brautbar C, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 2001;29:362-70.
15. Bonnefoy-Berard N, Genestier L, Flacher M, Rouault JP, Lizard G, Mutin M, et al. Apoptosis induced by polyclonal antilymphocyte globulins in human B-cell lines. Blood 1994;83:1051-9.
16. Ayuk F, Fang L, Fehse B, Zander AR, Kröger N. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. Exp Hematol 2005;33:1531-6.
17. Zand MS, Vo T, Pellegrin T, Felgar R, Liesveld JL, Ifthikharuddin JJ, et al. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood 2006;107:2895-903.
18. Timm MM, Kimlinger TK, Haug JL, Kline MP, Greipp PR, Rajkumar SV, et al. Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. Leukemia 2006;20:1863-9.
19. Perez-Simon JA, Sureda A, Fernandez-Aviles F, Sampol A, Cabrera JR, Caballero D, et al. Reduced intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 2006; 20:542-5.
20. Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004;10:698-708.
21. Perez-Simon JA, Martino R, Alegre A, Tomas JF, De Leon A, Caballero D, et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation Br J Hematol 2003;121:104-8.
22. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GvHD Grading. Bone Marrow Transplant 1995;15:825-8.
23. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathological study of 20 Seattle patients. Am J Med 1980;69:204-17.
24. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. on behalf of the Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant), Chronic Leukaemia Working, Party and the Myeloma Working Committee of the, IBMTR (International Bone, Marrow Transplant Registry), and ABMTR (Autologous Blood, and Marrow Transplant Registry). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
25. Zander AR, Zabelina T, Kröger N, Renges H, Krüger W, Löliger C, et al. Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 1999;23:889-93.
26. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002;99:1071-8.
27. Fang L, Fehse B, Engel M, Zander A, Kroger N. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation 2005 15;79:369-71.
28. Kroger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, et al. Comparison between anti-thymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005;129:631-43.
29. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969-76.
30. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, et al. Melphalan and purine analog-containing preparative regimens: reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-7.
31. Eiermann TH, Lambrecht P, Zander AR. Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 1999;23:779-81.
32. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G for the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Reduced intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588-94.
33. Remberger M, Sunderg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005;90:931-8.
34. Bacigalupo A, Lamparelli T, Gualandi F, Bregante S, Raiola AM, Di Grazia C, et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplantation. Biol Blood and Marrow Transplant 2002;8:656-61.
35. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplant-related mortality. Blood 2002;100:3919-24.
36. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft versus host disease prophylaxis including anti-T lymphocyte globulin. J Clin Oncol 2003;21:506-13.